Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $15.69, for a total value of $188,280.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Samuel Kintz also recently made the following trade(s):

  • On Tuesday, December 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $14.64, for a total value of $175,680.00.
  • On Friday, December 22nd, Samuel Kintz sold 8,175 shares of Enliven Therapeutics stock. The stock was sold at an average price of $13.05, for a total value of $106,683.75.
  • On Wednesday, December 20th, Samuel Kintz sold 7,779 shares of Enliven Therapeutics stock. The stock was sold at an average price of $13.01, for a total value of $101,204.79.
  • On Friday, November 3rd, Samuel Kintz sold 8,026 shares of Enliven Therapeutics stock. The shares were sold at an average price of $13.08, for a total value of $104,980.08.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $16.28 on Wednesday. The stock’s fifty day moving average price is $12.97 and its two-hundred day moving average price is $14.21. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $25.34. The company has a market cap of $667.48 million, a price-to-earnings ratio of 5.09 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last released its earnings results on Thursday, November 9th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). On average, equities analysts predict that Enliven Therapeutics, Inc. will post -2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics in the 4th quarter worth about $66,000. SG Americas Securities LLC grew its position in shares of Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after acquiring an additional 2,041 shares during the period. Exchange Traded Concepts LLC grew its position in shares of Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Enliven Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,151,817 shares of the company’s stock valued at $15,734,000 after buying an additional 9,313 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Read More

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.